An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia

Trial Profile

An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms CheckMate870
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 30 Jul 2022 to 30 Jul 2020.
    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top